Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum

May 11, 2021 updated by: University of Arizona
The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student population. Students will be provided the opportunity to opt-in to test their own pharmacogenomic panel while participating in the standard curriculum. Students will have the option of using their own reports or dummy reports during classroom activities. Our hypothesis is that those students who have their own pharmacogenomics tested will show better overall performance.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

233

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Willingness to provide informed consent for participation in the study
  • Enrolled in 3rd year Doctor of Pharmacy course

Exclusion Criteria:

  • Unwilling or unable to provide consent for participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Personal genomic educational testing (PGET)
PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment
Genetic: Personal genomic educational testing (PGET)
PGET consisted of a panel of pharmacogenomic variants
Placebo Comparator: No personal genomic educational testing (NPGET)
No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.
Genetic: No personal genomic educational testing (NPGET)
Lack of pharmacogenomic testing

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pharmacogenomics Knowledge Assessment
Time Frame: 8-12 weeks
Improvement in performance on a knowledge assessment including eleven questions
8-12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self Assessment Questionnaire
Time Frame: 8-12 weeks
Improvement in Likert Scale Responses for 27 questions (scale of 1[worst] to 6[best])
8-12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Arizona

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2016

Primary Completion (Actual)

March 1, 2021

Study Completion (Actual)

March 1, 2021

Study Registration Dates

First Submitted

May 4, 2021

First Submitted That Met QC Criteria

May 11, 2021

First Posted (Actual)

May 17, 2021

Study Record Updates

Last Update Posted (Actual)

May 17, 2021

Last Update Submitted That Met QC Criteria

May 11, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 1602413309

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe